0001437749-14-018189.txt : 20141015 0001437749-14-018189.hdr.sgml : 20141009 20141009140153 ACCESSION NUMBER: 0001437749-14-018189 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20141009 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20141009 DATE AS OF CHANGE: 20141009 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VIVEVE MEDICAL, INC. CENTRAL INDEX KEY: 0000879682 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 043153858 STATE OF INCORPORATION: B0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11388 FILM NUMBER: 141149895 BUSINESS ADDRESS: STREET 1: 150 COMMERCIAL STREET CITY: SUNNYVALE STATE: CA ZIP: 94086 BUSINESS PHONE: 4085301900 MAIL ADDRESS: STREET 1: 150 COMMERCIAL STREET CITY: SUNNYVALE STATE: CA ZIP: 94086 FORMER COMPANY: FORMER CONFORMED NAME: PLC SYSTEMS INC DATE OF NAME CHANGE: 19930328 8-K 1 plcsf20141009_8k.htm FORM 8-K plcsf20141009_8k.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 9, 2014

 

VIVEVE MEDICAL, INC.

(Exact name of registrant as specified in its charter)

 

Yukon Territory, Canada

1-11388

04-3153858

(State or other jurisdiction of

incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

150 Commercial Street

Sunnyvale, California

94086

(Address of principal executive offices)

(Zip Code)

 

 

 

Registrant’s telephone number, including area code: (408) 530-1900

 

No change


(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

 

Item 7.01            Regulation FD Disclosure.

 

On October 9, 2014, Viveve Medical, Inc. issued a press release announcing that it will be presenting at the 16th World Meeting on Sexual Medicine held in Sao Paolo, Brazil from October 8 through October 12, 2014. A copy of the press release is filed herewith as Exhibit 99.1. 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

 

Exhibit

No.

Description

99.1

Press Release dated October 9, 2014

 

 
 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: October 9, 2014  

 

 

 

VIVEVE MEDICAL, INC. 

 

 

 

 

 

 

 

 

 

 

 

 

 

By: 

/s/ Scott Durbin

 

 

 

 

Scott Durbin

 

 

 

 

Chief Financial Officer 

 

 

 

EX-99 2 ex99-1.htm EXHIBIT 99.1 ex99-1.htm

 

Exhibit 99.1

 

Viveve Announces Presentation at World Meeting on Sexual Medicine

 

 

 

SUNNYVALE, California.—October 9, 2014 – Viveve Medical, Inc. (“Viveve”)(OTC PINK: PLCSD), a company focused on women’s health, has announced that today Dr. Michael Krychman will present on the Viveve System as a non-invasive treatment for vaginal introital laxity to improve sexual function in adult females during the 16th World Meeting on Sexual Medicine which is taking place in Sao Paulo, Brazil from October 8-12, 2014.

 

The presentation highlighted the results from two clinical studies in which the Viveve® System, a non-surgical, non-ablative medical device, is used treat vaginal laxity which results from the over-stretching of the vaginal tissue during childbirth, and for other reasons. The treatment works by remodeling collagen and restoring the tissue in the vaginal introitus. The studies, conducted in the United States and Japan, demonstrated that the 30-minute, outpatient procedure resulted in a statistically significant improvement in vaginal laxity and sexual satisfaction in women to their pre-childbirth levels.

 

According to Dr. Krychman, a world renowned specialist in sexual health and the Executive Director of The Southern California Center for Sexual Health and Survivorship, “These results show that patients demonstrated significant improvement after treatment with the Viveve System. With excellent efficacy, a strong safety profile, and fast patient recovery, the Viveve Treatment allows doctors to address a condition that can profoundly impact a woman’s quality of life.”

 

“This presentation highlights the unique capabilities of the Viveve System” said Patricia Scheller, CEO of Viveve. “It is the only procedure that is simple, does not require anesthesia or analgesics, and for which there are no post-operative patient restrictions or lengthy recovery times.”

 

About Viveve

 

Viveve, Inc., the operating subsidiary of Viveve Medical, Inc., is a women’s health company passionately committed to advancing new solutions to improve women’s overall well-being and quality of life. The company’s lead product, the Viveve® System, is a non-surgical, non-ablative medical device that remodels collagen and restores tissue. The Viveve System treats the condition of vaginal laxity, which is the result of the over-stretching of tissue during childbirth, which can result in a decrease in sexual function and physical sensation. Physician surveys indicate that vaginal laxity is the number one post-delivery physical change for women, being more prevalent than weight gain, urinary incontinence or stretch marks. The Viveve Treatment uses patented, reverse-thermal gradient radiofrequency technology to tighten the tissues of the vaginal introitus (opening) and requires only a 30-minute out-patient treatment in a physician’s office. The Viveve System has received regulatory approval in Europe, Canada and Hong Kong and is available through physician import license in Japan. It is currently not available for sale in the U.S.

 

Safe Harbor Statement

 

All statements in this press release that are not based on historical fact are “forward looking statements”. While management has based any forward looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are to be detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

 

Viveve, Viveve System, Viveve Treatment and Viveve Procedure are registered trademarks of Viveve, Inc.

 

Contact:

Investor Relations

Booke and Company Inc.

600 Third Ave.

New York, NY 10016

212-490-9095

admin@bookeandco.com